Comparability and biosimilarity assessment in EU MCQs With Answer

Introduction

This quiz collection on “Comparability and biosimilarity assessment in EU” is designed for M.Pharm students to deepen understanding of regulatory requirements and scientific principles governing biologicals and biosimilars in the European Union. It covers the stepwise comparability approach, analytical and functional characterisation, non-clinical and clinical data expectations, reference product selection and bridging, immunogenicity assessment, extrapolation of indications, and regulatory guidance such as ICH Q5E and EMA biosimilar guidelines. Questions are structured to reinforce key concepts used in dossier preparation and regulatory assessment, and to prepare students for real-world application in pharmaceutical development and regulatory affairs.

Q1. Which document is the primary international guideline for assessing comparability following manufacturing changes for biological medicinal products?

• ICH Q8: Pharmaceutical Development
• ICH Q5E: Comparability of Biotechnological/Biological Products
• EMA Guideline on Good Clinical Practice
• WHO Technical Report Series on Vaccines

Correct Answer: ICH Q5E: Comparability of Biotechnological/Biological Products

Q2. In the EU biosimilar regulatory pathway, what is the preferred reference for comparisons?

• A non-authorised copy from a third country
• The innovator product authorised in the EU (EU reference medicinal product)
• An in-house produced molecule with similar sequence
• A pooled historical dataset from literature

Correct Answer: The innovator product authorised in the EU (EU reference medicinal product)

Q3. What is the main purpose of the stepwise comparability exercise for biosimilars?

• To replace clinical trials entirely
• To progressively build evidence from analytical to clinical to demonstrate similarity
• To determine pricing and reimbursement status
• To establish manufacturing site locations

Correct Answer: To progressively build evidence from analytical to clinical to demonstrate similarity

Q4. Which of the following is considered a critical quality attribute (CQA) for monoclonal antibody biosimilars?

• Packaging label font size
• Glycosylation profile affecting Fc effector functions
• Marketing strategy in member states
• Batch release economics

Correct Answer: Glycosylation profile affecting Fc effector functions

Q5. When a biosimilar developer uses a non-EU authorised reference product, what is typically required by EMA?

• No additional data if the molecule is identical
• A bridging study to demonstrate comparability between the non-EU reference and the EU reference
• Only in vitro data comparing to the non-EU reference
• A global marketing authorisation application instead of EU application

Correct Answer: A bridging study to demonstrate comparability between the non-EU reference and the EU reference

Q6. Which analytical strategy is most important as the first step in a biosimilarity assessment?

• Large phase III clinical endpoint trial
• Extensive physicochemical and functional characterisation using orthogonal methods
• Health economics analysis
• Patient-reported outcome surveys

Correct Answer: Extensive physicochemical and functional characterisation using orthogonal methods

Q7. In EU guidance, extrapolation of indications for a biosimilar is allowed when:

• The biosimilar has been tested in every possible clinical indication
• Scientific justification shows mechanism of action, receptor expression and clinical data support extrapolation
• Marketing authorisation holder pays an additional fee
• The biosimilar has a different primary sequence but same name

Correct Answer: Scientific justification shows mechanism of action, receptor expression and clinical data support extrapolation

Q8. What clinical study type is commonly used to demonstrate pharmacokinetic similarity between a biosimilar and its reference?

• Randomised, double-blind, parallel-group equivalence PK study in healthy volunteers or patients
• Open-label single-arm safety study
• Cross-sectional prescription audit
• Case series of adverse events

Correct Answer: Randomised, double-blind, parallel-group equivalence PK study in healthy volunteers or patients

Q9. What statistical acceptance range is typically applied to demonstrate equivalence for PK parameters (AUC and Cmax) in biosimilar studies?

• 50–150%
• 90–110%
• 80–125%
• 70–130%

Correct Answer: 80–125%

Q10. Which of the following best describes the EMA position on interchangeability and automatic substitution of biosimilars?

• EMA centrally decides interchangeability and mandates automatic substitution across EU
• EMA prohibits any switching between biosimilars and reference products
• EMA provides scientific assessment of biosimilarity, while interchangeability/substitution decisions are left to Member States
• EMA requires pharmacists to substitute biosimilars automatically for cost reasons

Correct Answer: EMA provides scientific assessment of biosimilarity, while interchangeability/substitution decisions are left to Member States

Q11. Which non-clinical evidence is considered most relevant in modern biosimilar development in the EU?

• Extensive animal toxicity studies regardless of analytical similarity
• Targeted in vitro functional assays and limited in vivo studies guided by residual uncertainty
• Long-term carcinogenicity studies in multiple species
• Market surveillance data of other products

Correct Answer: Targeted in vitro functional assays and limited in vivo studies guided by residual uncertainty

Q12. Immunogenicity assessment for a biosimilar should include which of the following?

• Only a single ADA assay at baseline
• Comparative immunogenicity testing with validated assays, including incidence, titre and clinical consequences
• No immunogenicity testing is needed if analytical similarity is proven
• Only post-marketing spontaneous reports

Correct Answer: Comparative immunogenicity testing with validated assays, including incidence, titre and clinical consequences

Q13. Which is a major difference between a comparability exercise for process changes and a biosimilarity exercise?

• Comparability compares two different active substances; biosimilarity compares two batches of same product
• Comparability typically involves the same manufacturer’s product pre- and post-change; biosimilarity compares independent manufacturers’ products
• Comparability is only about clinical data; biosimilarity only about analytics
• There is no regulatory guidance for comparability

Correct Answer: Comparability typically involves the same manufacturer’s product pre- and post-change; biosimilarity compares independent manufacturers’ products

Q14. Which analytical attribute is especially important to evaluate for aggregation in biologics?

• pH of the container label
• Size-exclusion chromatography and orthogonal methods to detect aggregates
• Employee training records
• Tablet hardness

Correct Answer: Size-exclusion chromatography and orthogonal methods to detect aggregates

Q15. What is the role of functional bioassays in biosimilarity assessment?

• They are optional and rarely informative
• They are central to demonstrate comparable biological activity and mechanism of action
• They replace the need for analytical characterisation
• They are used only for small molecule generics

Correct Answer: They are central to demonstrate comparable biological activity and mechanism of action

Q16. If residual uncertainty remains after analytical and non-clinical comparison, EMA typically expects:

• No further data and immediate approval
• Appropriate clinical data such as comparative clinical efficacy or PK/PD studies
• Only a manufacturing audit
• A change of the reference product

Correct Answer: Appropriate clinical data such as comparative clinical efficacy or PK/PD studies

Q17. During the regulatory review for a biosimilar, which documentation is critical in the Chemistry, Manufacturing and Controls (CMC) section?

• Clinical study participant names
• Detailed description of cell line, manufacturing process, control strategy and comparability data
• Only the marketing plan
• Pricing agreements with payers

Correct Answer: Detailed description of cell line, manufacturing process, control strategy and comparability data

Q18. For monoclonal antibody biosimilars, which factor must be justified when extrapolating to an indication where ADCC is relevant but not directly studied?

• That the product packaging is identical
• That functional assays and analytical data demonstrate comparable ADCC-related attributes and receptor interactions
• That the clinical trial was cheaper than reference trials
• That the originator’s patent has expired

Correct Answer: That functional assays and analytical data demonstrate comparable ADCC-related attributes and receptor interactions

Q19. What is the EMA’s expectation regarding post-authorisation safety monitoring for biosimilars?

• No post-authorisation monitoring is required
• Routine pharmacovigilance plus any specific risk management measures as needed, including immunogenicity monitoring
• Only periodic safety update reports without real-world data
• Immediate withdrawal after two years

Correct Answer: Routine pharmacovigilance plus any specific risk management measures as needed, including immunogenicity monitoring

Q20. Which statement best describes the EMA’s approach to naming of biosimilars?

• EMA requires a unique INN with a mandatory suffix for all biosimilars
• EMA uses the same INN system as for other medicines; biosimilars typically have the same INN but distinct brand names and labelling to ensure traceability
• EMA prohibits use of the originator’s INN for biosimilars
• EMA mandates anonymous naming without brand identifiers

Correct Answer: EMA uses the same INN system as for other medicines; biosimilars typically have the same INN but distinct brand names and labelling to ensure traceability

Download